IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

Authors

Pavel A Nikitin, Immunome Inc.
Suzanne M Scheaffer, Washington University School of Medicine in St. Louis
Michael S Diamond, Washington University School of Medicine in St. Louis
Et al

Journal

Science Immunology

Publication Date

9-9-2022

Volume

7

Issue

75

First Page

eabl9943

Document Type

Open Access Publication

DOI

10.1126/sciimmunol.abl9943

Rights and Permissions

Nikitin PA, DiMuzio JM, Dowling JP, Patel NB, Bingaman-Steele JL, Heimbach BC, Henriquez N, Nicolescu C, Polley A, Sikorski EL, Howanski RJ, Nath M, Shukla H, Scheaffer SM, Finn JP, Liang LF, Smith T, Storm N, McKay LGA, Johnson RI, Malsick LE, Honko AN, Griffiths A, Diamond MS, Sarma P, Geising DH, Morin MJ, Robinson MK. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. Sci Immunol. 2022 Sep 9;7(75):eabl9943. doi: 10.1126/sciimmunol.abl9943 This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Nikitin, Pavel A; Scheaffer, Suzanne M; Diamond, Michael S; and Et al, "IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2." Science Immunology. 7, 75. eabl9943 (2022).
https://digitalcommons.wustl.edu/oa_4/416